Published October 25, 2011
The UB Clinical and Translational Research Center’s first annual colloquium highlighted studies and novel technologies designed at UB and Roswell Park Cancer Institute to speed the time it takes new medical tests and treatments to go from the laboratory to patients.
Area scientists, researchers and clinicians attended the Oct. 21 event at the Roswell Park Center for Genetics and Pharmacology.
Investigators who presented their research at the colloquium had won pilot study grants from the UB CTRC.
Their projects were selected because they involve
interdisciplinary collaboration and were determined to have
greatest potential to receive external funding, explains Timothy
F. Murphy, MD, senior associate dean for clinical and
translational research and SUNY Distinguished Professor of Medicine.
Awardees and the research studies they presented at the colloquium are as follows:
Olagnostic and prognostic potential of serum mRNA expression in prostate cancer, which studies the use of microRNA as a biomarker for characterizing prostate cancer
System pharmacological analysis of molecularly target agents in pancreatic cancer: pharmacodynamic design of novel therapeutic trials to develop a new predictive pharmacologic model to better understand drug-cancer-patient interactions in pancreatic cancer
Use of niacin to overcome aspirin resistance, to study niacin’s use in people with low HDL cholesterol
Proteomic analysis of laser microdissected biopsy samples: transforming individualized therapy of prostate cancer, to identify potential disease/therapy markers in prostate cancer tissues from biopsy samples
Development of a small animal single photon emission computed tomography and computed tomography dual functional imager with an X-ray detector, to develop better ways to do non-invasive, in vivo animal imaging
The following entities allocated a total of $200,000 to support the pilot study grants:
round of funding, which will also total $200,000, is currently
“This support, especially in these tight financial times,
demonstrates a powerful commitment on behalf of clinical and
translational science here in Buffalo,” says Murphy.
Steven J. Fliesler, PhD, directs the award program for Novel Clinical and Translational Methodologies. He is the Meyer H. Riwchun Endowed Chair Professor, vice chair and director of research in the Department of Ophthalmology and Ira G. Ross Eye Institute Vision Research Center. Fliesler is also a research health scientist at the Buffalo VA Medical Center.